Press Releases

Press Releases

International Vaccine Institute and Technical University of Denmark to strengthen external quality assurance in the face of rising antimicrobial resistance in Asia

IVI and Sweden renew partnership to accelerate vaccines for global public health

IVI to lead critical standard reagents availability for oral cholera vaccine manufacturing to ensure their uniform efficacy and help meet global demand

IVI appoints three new members to its Board of Trustees

IVI to Accelerate Efforts in iNTS Vaccine Development

IVI acquires GCLP certification from Korean Ministry of Food and Drug Safety

IVI Awarded $4.5 Million Grant to Increase Accessibility of Oral Cholera Vaccine

IVI Discusses Expanding Support for Global Collaboration on Vaccine R&D and Delivery with Top Foreign Diplomats in Seoul

IVI-led Consortium Awarded Fleming Fund Regional Grant to Improve Data Sharing in Fight against Antimicrobial Resistance

IVI to help developing countries tackle the spread of infectious diseases by building capacity through vaccinology training in Seoul

IVI acquires supplemental funding for Severe Typhoid in Africa Program (SETA Plus)

IVI Director General Dr. Jerome Kim to join the Human Vaccines Project’s Efforts as One of Four Distinguished Global Leaders to Decode the Human Immune System

Prof. Young Chul Sung, biotech leader, personally donates US$8.4 million to IVI

New push to develop world’s first vaccine against the deadly Strep A bacteria killing hundreds of thousand

IVI-led CAPTURA consortium wins Fleming Fund award for work on antimicrobial resistance (AMR) data across Asia

IVI receives $15.7 million grant to conduct phase III trials of new Vi-DT typhoid conjugate vaccine manufactured by SK bioscience of Korea

‘IVI Forum for Enhancement of Cooperation’ hosted jointly by the Korean Parliamentary Forum for Global Health, and KCDC under MOHW

Vaccine study confirms sensitivity of cholera test

Korean Pediatric Association, IVI, KSC exchange MOU

IVI receives $3.2 million grant to support TCV effectiveness studies in West Africa

CEPI partners with IVI to accelerate development of vaccines against emerging global health threats

Henry Lau joins IVI as Goodwill Ambassador

Nature Communications study addresses MDR typhoid

THSTI, IVI held joint symposium on Nov. 22

‘The Euvichol story’ published in Vaccine

IVI accelerates development of MERS vaccine

IVI’s 18th Vaccinology Course gathers 120 international participants from 19 countries in Seoul September 3-7

KOICA, IVI team up with Mozambican MoH and INS, partners to vaccinate 190,000 people against cholera

IVI acquires $5 million grant to support process development, scale up of typhoid conjugate vaccine with SK Bioscience


WHO and IVI Hold Joint Symposium for MERS-CoV Vaccine Development in Seoul on June 26, 27

2018-06-26 11:32
- 120 experts and professionals are updating progress in MERS human and dromedary camel vaccine development, seeking next steps

- Symposium co-hosted by WHO and convened as the 4th IVI Global Vaccine Forum sponsored by WHO, Seoul Cyber University, Korea Support Committee for IVI

The World Health Organization (WHO) and the International Vaccine Institute (IVI) are holding a symposium for MERS-CoV vaccine development in Seoul on June 26 and 27.  The one and half-day conference is reviewing progress in Middle East Respiratory Syndrome Coronavirus (MERS-CoV) human and dromedary camel vaccine research and development, and determining next steps towards MERS vaccines.

The WHO-IVI Joint Symposium for MERS-CoV Vaccine Development brings together more than 120 experts and professionals from industry, academia, international organizations and government agencies around the world, including the Coalition for Epidemic Preparedness Innovations (CEPI), the Korean Ministry of Food and Drug Safety (KMFDS) and the Korea Centers for Disease Control and Prevention (KCDC).

The symposium provides a forum to update the status of animal and human MERS-CoV vaccine development, and identifies and prioritizes activities to accelerate vaccine R&D. The information shared during the symposium will be used to inform the WHO R&D Roadmap for MERS-CoV vaccines.

The symposium is discussing progress of the WHO R&D Blueprint for action to prevent epidemics of MERS, recent advancements in MERS-CoV human and dromedary vaccines by developers (including GeneOne Life Sciences, the Jenner Institute, and the German Center for Infection Research), and regulatory pathways, among other agenda items.

MERS-CoV is an emerging pathogen with the potential to pose a serious threat to global public health. Sporadic human cases and outbreaks continue to be reported in the Middle East, and case fatality rates remain high at approximately 35% globally. The MERS outbreak in Korea in 2015 sparked international concerns about potential global dissemination of this virus. No specific preventive or therapeutic countermeasures currently exist.

“This symposium is a continuation of discussions by many partners about the development and potential use of MERS-specific vaccines in dromedary camels and humans,” said Dr. Maria Van Kerkhove, MERS-CoV Technical Lead at WHO. “Accelerating development of vaccines for this high threat pathogen is critical to prevent human infections.”

Along with Lassa Fever and Nipah viruses, MERS-CoV is one of three pathogens prioritized for vaccine development by CEPI, a global alliance launched in 2017 to finance and coordinate the development of vaccines to prevent and contain emerging diseases with pandemic potential.

“Safe and effective vaccines in humans and dromedary camels could play an important role in reducing the threat from the virus,” said Dr. In-Kyu Yoon, the head of IVI’s MERS program. “The symposium provides a timely opportunity to present the state-of-the art in MERS-CoV vaccine R&D, and help coordinate private and public sector efforts in the quest to develop MERS-CoV vaccines.”

The WHO-IVI MERS-CoV Symposium is the 4th IVI Global Vaccine Forum sponsored by Seoul Cyber University and the Korea Support Committee for IVI; and, this year, is part of the larger Global Bio Conference (GBC) 2018, taking place from June 26 to 29 and hosted by KMFDS.